Genmab Announces Financial Results for the First Half of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Genmab Announces Financial Results for the First Half of 2014 and Improves 2014 Financial Guidance

August 13, 2014; Copenhagen, Denmark;
Interim Report First Half 2014

  • Announced three new Phase III studies of daratumumab in multiple myeloma and improved guidance twice
  • Achieved USD 25 million milestone payment under Janssen Biotech, Inc. collaboration for daratumumab
  • Arzerra® (ofatumumab) label expansion in US and EU for first-line chronic lymphocytic leukemia (CLL)
  • Phase III PROLONG study of ofatumumab maintenance therapy in relapsed CLL met primary endpoint at interim analysis
  • Announced GSK plans to start pivotal studies of subcutaneous ofatumumab in relapsing-remitting multiple sclerosis (RRMS) and neuromyelitis optica (NMO)
  • Signed first HexaBody™ technology platform research collaboration agreement
  • Reported topline data from two Phase III studies of ofatumumab – primary endpoints not met
  • Improved operating result by DKK 54 million over H1 2013

“We continue to make solid progress across our business as the year progresses.  The label expansion for Arzerra to include treatment of first-line patients with CLL in the US in combination with chlorambucil in April was followed closely by approval in Europe for Arzerra in combination with chlorambucil or bendamustine.  We were pleased to announce that the Phase III study of ofatumumab as maintenance therapy in relapsed CLL met its primary endpoint at an interim analysis.  Furthermore, we announced three new Phase III studies of daratumumab in combination with backbone therapies, one in relapsed or refractory multiple myeloma and two in first line multiple myeloma.  In July we reached a USD 25 million milestone based on progress in the first Phase III study under our collaboration with Janssen and have again been able to improve our financial guidance,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

Financial Performance First Half

  • Genmab’s revenue increased DKK 65 million or 22% to DKK 363 million in the first half of 2014. The increase was mainly driven by higher revenue related to our daratumumab collaboration with Janssen Biotech, Inc. (“Janssen”); partly offset by lower milestones and royalties related to our collaboration with GSK.
  • Operating expenses were DKK 298 million in the first half of 2014, compared to DKK 287 million in the first half of 2013, an increase of DKK 11 million or 4%.
  • Operating income was DKK 65 million in the first half of 2014 compared to an operating income of DKK 11 million in the corresponding period for 2013, an improvement of DKK 54 million, which was driven by increased revenue, partly offset by the increase in operating expenses.
  • On June 30, 2014, Genmab had a cash position of DKK 2,584 million. This represented a net increase of DKK 1,027 million from the beginning of 2014. The increase was driven by net proceeds of DKK 972 million received from the private placement in January 2014.

Business Progress Second Quarter to Present

Ofatumumab

  • July: An Independent Data Monitoring Committee (IDMC) interim analysis of a Phase III study, PROLONG, evaluating ofatumumab maintenance therapy versus no further treatment (observation) in patients with relapsed CLL who responded to treatment at relapse, reached the predefined significance level for efficacy (p<0.001). The interim analysis demonstrated that treatment with ofatumumab met the primary endpoint of improving progression free survival (PFS).
  • July: GlaxoSmithKline (GSK) reported net sales for Arzerra for the second quarter of 2014 of GBP 12.8 million, resulting in royalty income of approximately DKK 23 million to Genmab.
  • July: Marketing authorization was granted in the EU for the use of Arzerra in combination with chlorambucil or bendamustine for the treatment of patients with CLL who have not received prior therapy and who are not eligible for fludarabine-based therapy.
  • June: Topline data from the Phase III study of ofatumumab versus physician’s choice in patients with bulky fludarabine-refractory CLL showed that the study did not meet its primary endpoint.
  • May: Announced that GSK has taken the decision to start Phase III studies of subcutaneous ofatumumab in RRMS in 2015, and plans to file an Investigational New Drug application (IND) for a potential pivotal study of subcutaneous ofatumumab in NMO in 2014.
  • May: Topline results from the Phase III study (ORCHARRD) of ofatumumab in combination with chemotherapy versus rituximab in combination with chemotherapy for relapsed or refractory DLBCL showed that the study did not meet its primary endpoint.
  • April: The US FDA approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra in combination with chlorambucil for the treatment of previously untreated patients with CLL for whom fludarabine-based therapy is considered inappropriate.

Daratumumab

  • August: Announced a Phase III study of daratumumab in combination with lenalidomide and dexamethasone compared to lenalidomide and dexamethasone alone as front line treatment for multiple myeloma patients who are not considered candidates for stem cell transplantation (SCT).  The study is planned to start in the first half of 2015.  
  • July: Announced a Phase III study of daratumumab in combination with bortezomib, melphalan and prednisone compared to bortezomib, melphalan and prednisone alone as front line treatment for multiple myeloma patients who are not considered candidates for SCT. The study is expected to start in the fourth quarter of 2014.
  • July: Reached the third milestone in the daratumumab collaboration with Janssen triggering a USD 25 million payment to Genmab for progress in the ongoing Phase III study of daratumumab in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone for the treatment of relapsed or refractory multiple myeloma.
  • May: A Phase III study investigating daratumumab in combination with bortezomib and dexamethasone versus bortezomib and dexamethasone alone for the treatment of relapsed or refractory multiple myeloma was announced. 2014 guidance was improved on May 1 due to the inclusion of an anticipated milestone related to this Phase III study.

Technology

  • July: Reached a milestone in the DuoBody technology platform collaboration with Janssen, triggering a USD 3 million milestone payment for pre-clinical progress with a DuoBody® product candidate in autoimmune disease.
  • June: Entered a research collaboration with an undisclosed major biotechnology company which will use and evaluate the DuoBody and HexaBody platforms.  This is the first collaboration for the HexaBody platform.

Outlook
Genmab is improving its 2014 financial guidance published on May 1, 2014, due to increased revenue.

Conference Call
Genmab will hold a conference call in English to discuss the results for the first half of 2014 today, Wednesday, August 13, at 6.00 pm CEST, 5.00 pm BST or noon EDT. The dial in numbers are:

+1 866 682 8490 (US participants) and ask for the Genmab conference call
+44 1452 555 131 (international participants) and ask for the Genmab conference call


A live and archived webcast of the call and relevant slides will be available at www.genmab.com .

Contact:           
Rachel Curtis Gravesen , Senior Vice President, Investor Relations & Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

The interim report contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the section “Risk Management” in Genmab’s annual report, which is available on www.genmab.com and the “Significant Risks and Uncertainties” section in the interim report. Genmab does not undertake any obligation to update or revise forward looking statements in the interim report nor to confirm such statements in relation to actual results, unless required by law.

CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark

Download the full Interim Report for the First Half 2014 on attachment or at www.genmab.com .

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 363

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 387

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 544

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 109

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 305

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 161

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 411

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 174

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 277

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading

Top 5 Most Recently Viewed Articles

Roche Unveils High-Sensitivity Troponin T Test Increasing Diagnosis Precision

Updated Category News Views 350

The Unveiling of Roche's Sixth-Generation Troponin T Test Roche has recently been granted a CE Mark for its innovative sixth-generation Troponin T test, which promises to deliver a new level of accuracy that is critical for diagnosing heart attacks. This novel testing solution is designed to enhance sensitivity and precision, allowing for quicker and more reliable...

Continue Reading
Maximize Your Earnings with Keurig Dr Pepper Stock Strategy

Updated Category News Views 133

Understanding Keurig Dr Pepper's Earnings Potential Keurig Dr Pepper Inc. (NASDAQ: KDP) is preparing to share its third quarter earnings results shortly. Investors eagerly await the disclosures, which are expected to highlight positive financial trends and growth. Analysts predict that the company will report earnings per share of 54 cents, an increase from 51 cents in...

Continue Reading
Uwharrie Capital Corp Celebrates Year-End Financial Growth

Updated Category News Views 113

Uwharrie Capital Corp Reports Strong Year-End Results Uwharrie Capital Corp and its subsidiary, Uwharrie Bank, have recently unveiled impressive financial results that reflect their continued strength and stability in the banking sector. The company reported consolidated total assets of $1.13 billion at the end of the reporting period, demonstrating a noticeable increase...

Continue Reading
Enhancing California's Tourism Appeal with Interactive Design

Updated Category News Views 148

Revolutionizing Tourism Through Interactive Web Design In today's fast-paced digital world, engaging younger travellers has become crucial for tourism boards in California. Digital Silk, an award-winning agency renowned for its expertise in digital marketing and web design, is leading the charge to inspire Generation Z and millennials by advocating for the adoption of...

Continue Reading
FOX News Digital Dominates October with Record-Breaking View Counts

Updated Category News Views 174

FOX News Digital Achieves Historic Success in October Leading YouTube with 377 Million Video Views During the month of October, FOX News Digital achieved outstanding milestones, topping the charts in multiplatform engagement. With a staggering 3.7 billion multiplatform minutes and 1.8 billion views, the platform outshined its competitors, establishing its dominance in the...

Continue Reading